Fredun Pharmaceuticals

Fredun Pharmaceuticals delivered a strong Q4 FY26 with revenue of ₹213 croreCurrent reported value: ₹213 crore. No comparable prior figure is available in the source record. (+27% YoY), EBITDA of ₹29.1 croreCurrent reported value: ₹29.1 crore. No comparable prior figure is available in the source record. (+67% YoY), and PAT of ₹11.1 croreCurrent reported value: ₹11.1 crore. No comparable prior figure is available in the source record. (+56% YoY). EBITDA margin expanded 326 bpsCurrent reported value: 326 bps. No comparable prior figure is available in the source record. to 13.67Current 13.7 crore vs previous available quarter 16 crore.%, driven by a favorable mix shift toward higher-margin new-age businesses (pet care, mobility, nutraceuticals) and operating leverage in the vintage business. Management guided for 25-30% top-line growth in FY27, with PAT margins expected to reach 10-12% over the next few years as demographic expansion for new products matures. Key growth drivers include the upcoming hormone/anti-aging product launch and the pet care platform Vagger.in. Risks include rising finance costs due to debt-funded growth and potential margin pressure from raw material inflation, though management believes these are manageable.